A prospective economic analysis of early outcome data from the Alliance A041202/ CCTG CLC.2 randomized phase III trial of bendamustine-rituximab compared with ibrutinib-based regimens in untreated older patients with chronic lymphocytic leukemia
      QxMD      Google Scholar   
Citation:
Clin Lymphoma Myeloma Leuk vol 21 (11) 766-74
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-external-user
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
3396  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Pharmacyclics, Inc.  
Grants:
U10CA180821, U10CA180882, UG1CA233331; U10CA180863, #704970 (CCTG)  
Corr. Author:
 
Authors:
                                         
Networks:
LAPS-MN026, LAPS-OH007   
Study
Alliance-A151905
Multiple Studies, or Legacy Studies in Alliance Study:
Alliance-A041202
Phases:
N/A, 3
Keywords: